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Computational Molecular Modeling of Alzheimer’s Drug Derivatives
Cathy Ulman ’09 and Dr. John Lutton 
Department of Chemistry, Kenyon College, Summer Science 2008
Beta-Secretase
Figure 3) Secondary structure of beta-secretase
Beta-secretase (BACE) is of interest to researchers because of its 
potential to slow down the actual progression of Alzheimer’s disease. 
Basically, researchers hope to interrupt the plaque formation pathway, 
which BACE is an integral part of. If a selective inhibitor for BACE can be 
found, plaque formation could be slowed down or even stopped, which 
could potentially slow down the progression of the disease instead of just 
treat the symptoms like Aricept does. 
Since no well-known drugs on the market inhibit BACE, two 
inhibitors, Inhibitor 2 (I2) and Inhibitor 3 (I3), found by Arun k. Ghosh and 
his colleagues were used as the starting points for making derivatives.4
Introduction:
Currently, over 5 million Americans suffer from the degenerative brain disease known as Alzheimer’s disease 
(AD). Alzheimer’s disease slowly destroys brain cells, which causes memory loss, behavioral changes, and eventually 
death. Alzheimer’s disease currently ranks as the 7th leading cause of death in the United States. Worst of all, it has 
no cure. Drugs like Aricept work to treat the symptoms of Alzheimer’s disease, but no drug currently on the market is 
able to stop the progression of Alzheimer’s disease completely.1
Everyone has trouble remembering things as they get older, but the severe memory loss associated with 
Alzheimer’s disease is completely different. Researchers believe that plaque buildup within the brain and the 
formation of neurofibrillary tangles cause some of this memory loss. Plaques may disrupt the ability of nerve cells to 
communicate effectively. An enzyme called beta-secretase cleaves amyloid precursor protein (APP) into smaller 
fragments called beta-amyloid fibrils (Aß fibrils), which then stick together to form the plaques. Plaques form between 
the nerve cells while tangles, which are made of tau protein, form within the dying cells.
In late stages of the disease, the brain noticeably shrinks due to the large amount of neuronal death. This 
shrinkage occurs due to a decrease in the size of the cortex, which controls our ability to think, plan, and remember. 
The hippocampus, which allows humans to make new memories, also becomes significantly smaller in late stage 
Alzheimer’s disease patients. Also, the water-filled ventricles, which are basically dead space in the brain because 
they contain no neurons, grow considerably.1
Aricept and Acetylcholinesterase
As many as 3.8 million patients have already used Aricept to 
slow down the progression of Alzheimer’s disease (AD), but Aricept 
is not a cure for AD. Aricept belongs to a group of drugs called N-
benzylpiperdine-based acetylcholinesterase (AChE) inhibitors.2
Aricept works by inhibiting the enzyme acetylcholinesterase, which 
basically means that the drug delays the breakdown of the 
neurotransmitter acetylcholine. This in turn increases the 
concentration of acetylcholine in synapses, which improves nerve 
cells’ communication and the Alzheimer’s patients’ ability to maintain 
their memory for years longer than they would be able to without 
Aricept.3
 
Figure 1) Secondary structure of acetylcholinesterase
Figure 2) Shows how beta and gamma secretase work to 
cleave APP. The portion of APP cleaved by gamma-secretase 
is called the cytoplasmic fragment, and the portion cleaved by 
beta-secretase is what forms the Aß plaques.
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Naming:
Early on in the project, a naming system was developed for organizing the many Hyperchem files, and to 
prevent calculations from being repeated multiple times. First, Aricept and the starting inhibitors in the BACE project 
were numbered (see below). 
Basically, if the hydrogen attached to 
carbon number 6 on Aricept were replaced
with a bromine then the file would be called
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Aricept Results
The table above shows the 5 best Aricept derivatives tried (out 
of 26). The best delta G values were found for derivatives that 
contained multiple halogens, especially iodine and bromine. Methyl, 
ethyl, and hydroxyl groups were also tried but did not have as good 
delta G values as the derivatives with halogens. 
Beta-Secretase Results
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The table above contains 
the 6 derivatives of inhibitor 2 that
had the best delta G values (out of 187). Like Aricept, the derivatives with 
multiple halogens were found to have the best delta G values, iodine 
especially. Also, changing the original ring on the left end of the molecule 
into a phenyl greatly improved the delta G value. Also, converting the 
hydroxyl group on carbon 25 into a carbonyl group is highly favorable. 
Future Goals: I would like to reduce the size of the inhibitor without 
compromising the delta G. A smaller molecule would be able to pass the 
blood brain barrier more easily, which would make it a more effective drug.
Derivative of Aricept
elta G (kcal/mol) ricept Delta G –
Derivative Delta G
erivative of Inhibitor 2 Delta G 
(kcal/mol)
Inhibitor 2 Delta G –
Derivative Delta G
Research Goal:
The goal of this project was to use the computational 
molecular modeling software, Hyperchem Professional, to 
make derivatives of known inhibitors and calculate the delta 
Gibbs free energies in an attempt to find derivatives that 
bind more strongly to their respective enzymes.
